2seventy bio Inc (NASDAQ:TSVT) has a beta value of 1.85 and has seen 2.62 million shares traded in the recent trading session. The company, currently valued at $251.12M, closed the recent trade at $4.96 per share which meant it gained $0.95 on the day or 23.69% during that session. The TSVT stock price is -155.85% off its 52-week high price of $12.69 and 69.15% above the 52-week low of $1.53. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.24 million shares traded. The 3-month trading volume is 1.37 million shares.
2seventy bio Inc (NASDAQ:TSVT) trade information
Sporting 23.69% in the green today, the stock has traded in the green over the last five days, when the TSVT stock price touched $4.96 or saw a fall of -2.27%. Year-to-date, 2seventy bio Inc shares have moved 16.16%, while the 5-day performance has seen it change 8.30%. Over the past 30 days, the shares of 2seventy bio Inc (NASDAQ:TSVT) have changed -14.04%. Short interest in the company has seen 5.59 million shares shorted with days to cover at 3.36.
2seventy bio Inc (TSVT) estimates and forecasts
Figures show that 2seventy bio Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 22.47% over the past 6 months, with this year growth rate of 69.23%, compared to 13.60% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 30.60% and 28.90% for the next quarter. Revenue growth from the last financial year stood is estimated to be -17.50%.
6 analysts offering their estimates for the company have set an average revenue estimate of $15.28 million for the current quarter. 6 have an estimated revenue figure of $19.09 million for the next quarter concluding in Jun 2024. Year-ago sales stood $22.3 million and $36.05 million respectively for this quarter and the next, and analysts expect sales will shrink by -31.50% for the current quarter and -47.00% for the next.
TSVT Dividends
2seventy bio Inc is expected to release its next earnings report between May 01 and May 06 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
2seventy bio Inc (NASDAQ:TSVT)’s Major holders
Insiders own 2.06% of the company shares, while shares held by institutions stand at 96.74% with a share float percentage of 98.77%. Investors are also buoyed by the number of investors in a company, with 2seventy bio Inc having a total of 171 institutions that hold shares in the company. The top two institutional holders are Kynam Capital Management, LP with over 4.89 million shares worth more than $49.49 million. As of Jun 29, 2023, Kynam Capital Management, LP held 9.69% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 4.14 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $41.85 million and represent 8.19% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Specialized-Health Care Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. As of Jul 30, 2023, the former fund manager holds about 4.06% shares in the company for having 2.05 million shares of worth $15.53 million while later fund manager owns 1.95 million shares of worth $10.1 million as of Aug 30, 2023, which makes it owner of about 3.86% of company’s outstanding stock.
